20
Participants
Start Date
February 26, 2025
Primary Completion Date
July 31, 2027
Study Completion Date
January 1, 2028
Pembrolizumab
Pembrolizumab is a highly selective immunoglobulin G4-kappa humanised monoclonal antibody against Programmed cell death protein 1 (PD-1) receptor. It was generated by grafting the variable sequences of a very high-affinity mouse antihuman PD-1 antibody onto a human IgG4-kappa isotype with the containing a stabilizing Serine 228 to Proline Fc mutation.
Olaparib
Olaparib is a potent inhibitor of polyadenosine 5'diphosphoribose polymerase (PARP) developed as a monotherapy as well as for combination with chemotherapy, ionising radiation and other anti-cancer agents including novel agents and immunotherapy.
RECRUITING
Addenbrooke's Hospital, Cambridge
RECRUITING
Velindre Cancer Centre, Cardiff
RECRUITING
University Hospitals Coventry and Warwickshire, Coventry
RECRUITING
Beatson West of Scotland Cancer Centre, Glasgow
RECRUITING
St James' University Hospital, Leeds
RECRUITING
Guy's and St Thomas' NHS Foundation Trust, London
RECRUITING
Royal Free Hospital, London
RECRUITING
University College London Hospitals NHS Foundation Trust, London
RECRUITING
The Christie, Manchester
RECRUITING
Milton Keynes University Hospital, Milton Keynes
RECRUITING
Norfolk and Norwich University Hospital, Norwich
RECRUITING
Nottingham University Hospitals NHS Foundation Trust, Nottingham
RECRUITING
Derriford Hospital, Plymouth
National Institute for Health Research, United Kingdom
OTHER_GOV
Cambridge University Hospitals NHS Foundation Trust
OTHER